Corporate Overview

When cancer is still localized it can be easily remove and patients are cured

Milagen, Inc. is a private Company. Since 1997, Milagen has been engaged in the discovery and development of non-invasive, easy-to-use immunodiagnostic products for the early detection, prognosis, and therapy management of cancers and other major diseases with unmet needs.

At Milagen, we applied our proprietary technologies to analyze patient tissues and biological fluids to discover and develop novel pharmaceutical products with clinical application for:
(a) Early detection of major cancers and other diseases
(b) Monitoring of disease progression and recurrence
(c) Therapeutic disease management

Milagen has discovered and thoroughly validated proprietary biomarkers for the early detection of several major cancers (lung cancer, colon cancer, prostate cancer, ovarian cancer, pancreatic cancer, etc). The Company is currently developing novel serum-based diagnostic products for the early detection of major cancers.

Milagen is developing a new generation of diagnostic products that can predict early disease stage, disease progression and therapy outcome using body fluids.